CardiAMP™ Cell Therapy for Heart Failure Trial
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 125 participants.
Also called NCT02438306
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 125 participants
- Sponsor
- BioCardia, Inc.
- Registry
-
NCT02438306
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- United States, Canada
- Registry status
- Completed
Technical summary
Registry record NCT02438306. Randomized; double masking; primary purpose treatment. Start 2016-12 (actual); primary completion 2025-02 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- CardiAMP™ Cell Therapy for Heart Failure Trial
- Condition
- Heart Failure, Systolic
- Intervention (Biological)
- Autologous cell therapy
- Intervention (Other)
- Sham
- Lead sponsor
- BioCardia, Inc.
Record details
- Record id
cardio:ct-nct02438306- Content hash
deebe89f51f47e656336a6e8c1503c5663eadee7992433b5a78c69e6f909ba67